ImmuneRegen BioSciences(R) Reports Positive Results of Homspera(R) in Treating Highly Pathogenic Influenza
Marketwire - Tue Nov 10, 8:00 am ETSCOTTSDALE, AZ--(Marketwire - 11/10/09) - ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTC.BB: IRBS - News ), today announced positive results from a study that evaluated its lead anti-Influenza drug, Homspera. The study in animals infected with H5N1 (or "Avian") Influenza virus , which is highly lethal to humans and animals, revealed that Homspera ...
